Tubulis
Science & Engineering · Biotechnology
Facts
as of Nov 17, 2026Tubulis is now part of Gilead Sciences. Tubulis to Present Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-resistant Ovarian Cancer in Rapid Oral Presentation at ASCO 2026.
- Legal name
- Tubulis GmbH
- Founded
- 2015
- Employees
- 501-1000estimated range
- Register numbers
- VAT DE325089835
- Official records
- Wikidata Q140045596
- Website
- tubulis.com
These are the key facts about Tubulis on Alion as of Nov 17, 2026. It was founded in 2015. It has raised $564M in 3 funding rounds. The latest round is Series C of $361M, announced in 2025.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Legal entity active
Tubulis GmbH
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Financials
Funding rounds, investors and revenue on record.
$564MTotal raised
$1.1MPublic grants4 public grants
GrantLatest round
7Rounds and grants
Money by yearUSD, rounds and grants
Largest rounds and grants
Sources: funding announcements, grant and company registers
Milestones
May 1
Won a grant $501k · CORDIS
Jan 21
Oct 15, 2025
Raised a round Series C $361M · YahooFinance
Apr 20, 2021
2015
Founded
Each milestone is dated by its source: registers, filings, the press
Newsroom
Apr 212026
News · YahooFinance
MUNICH, April 21, 2026--Tubulis today announced that an abstract covering current clinical trial data from its ongoing Phase I/IIa NAPISTAR 1-01 trial (NCT06303505) has been acce…
Apr 72026
News · MedCity News
Gilead Sciences' Tubulis acquisition brings antibody drug conjugates in clinical development for cancer. Analysts say the Tubulis platform technologies that yielded these ADCs co…
Jan 212026
News · YahooFinance
MUNICH, January 21, 2026--Tubulis today announced the publication of preclinical proof-of-concept data for its novel Alco5 conjugation platform in Nature Communications. The pape…
Oct 15, 20252025
News · Pulse 2.0
Tubulis: €308 Million Series C Secured To Advance Clinical Development Of Lead ADC Candidate TUB-040
Tubulis announced the closing of a €308 million ($361 million) Series C financing round aimed at accelerating the clinical development of its lead antibody-drug conjugate (ADC) c…
Oct 15, 20252025
News · STAT
The company, which is developing antibody-drug conjugates, will use the funding to push its lead drug candidate into trials in additional types of cancer.
Oct 15, 20252025
News · YahooFinance
The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer drug that's currently in early-stage testing.
Sources: the outlets named on each headline, each story once
